Adjuvant therapy for colon cancer

Current Gastroenterology Reports

Volumn 9, Issue 5, 2007, Pages 415-421

  Aranha, Olivia ^b   Benson III, Al B ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; BEVACIZUMAB; CAPECITABINE; EDRECOLOMAB; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LEVAMISOLE; OXALIPLATIN; SEMUSTINE; UFT; VINCRISTINE; ANTINEOPLASTIC AGENT;

ABDOMINAL PAIN; ADJUVANT THERAPY; ADVANCED CANCER; ALLELE; ASTHENIA; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER IMMUNOTHERAPY; CANCER LOCALIZATION; CANCER RELAPSE; CANCER STAGING; CHEMOTHERAPY INDUCED EMESIS; CHROMOSOME 18Q; CLINICAL TRIAL; COLON CANCER; COLON RESECTION; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG FEVER; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FLU LIKE SYNDROME; FOLLOW UP; GASTROINTESTINAL TOXICITY; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; LEUKOPENIA; LIVER DYSFUNCTION; LOW DRUG DOSE; MICROSATELLITE INSTABILITY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROLOGIC DISEASE; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; PROGNOSIS; RECURRENCE RISK; RESPIRATORY TRACT DISEASE; REVIEW; SKIN DISEASE; STOMATITIS; UNSPECIFIED SIDE EFFECT; ADJUVANT CHEMOTHERAPY; AGED; CANCER INVASION; COLON TUMOR; FEMALE; IMMUNOHISTOCHEMISTRY; MALE; METHODOLOGY; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SURVIVAL; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLECTOMY; COLONIC NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 38849086811     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-007-0052-x     Document Type: Review

References (47)

1. Jemal A, Siegel R, Ward E, et al.: Cancer statistics, 2007. CA Cancer J Clin 2007, 57:43-66.
2. Jessup JM, Stewart A, Greene FL, et al.: Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age, and differentiation. JAMA 2005, 294:2703-2711.
3. Greene FL, Page DL, Fleming ID, et al.: AJCC Cancer Staging Handbook, edn 6. New York: Springer-Verlag; 2002.
4. Greene FL, Stewart AK, Norton HJ: A new TNM staging strategy for node-positive (stage III) colon cancer: An analysis of 50,042 patients. Ann Surg 2002, 236:416-421.
5. Gill S, Loprinzi CL, Sargent DJ, et al.: Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 2004, 22:1797-1806.
6. Desch CE, Benson AB, Somerfield MR, et al.: Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2005, 23:8512-8519.
7. Compton C: Pathology report in colon cancer: what is prognostically important? Dig Dis 1999, 17:67-79.
8. Green RJ, Metlay JP, Propert K, et al.: Surveillance for second primary colorectal cancer after adjuvant chemotherapy: an analysis of Intergroup 0089. Ann Intern Med 2002, 136:261-269.
9. Le Voyer TE, Sigurdson ER, Hanlon AL, et al.: Colon cancer survival is associated with increasing number of lymph nodes analyzed: A secondary survey of intergroup trial INT-0089. J Clin Oncol 2003, 21:2912-2919.
10. Swanson RS, Compton CC, Stewart AK, et al.: The prognosis of T3N0 colon cancer is dependent on the number of lymph nodes examined. Ann Surg Oncol 2003, 10:65-71.
11. Compton CC: Key issues in reporting common cancer specimens: problems in pathologic staging of colon cancer. Arch Pathol Lab Med 2006, 130:318-324.
12. International Multicentre Pooled Analysis of Colon Cancer Trials Investigators (IMPACT): Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995, 345:939-944.
13. International Multicentre Pooled Analysis of Colon Cancer Trials Investigators (IMPACT): Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. J Clin Oncol 1999, 17:1356-1363.
14. Haller DG, Catalano PJ, Macdonald JS, et al.: Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol 2005, 23:8671-8678.
15. Poplin EA, Benedetti JK, Estes NC, et al.: Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer. J Clin Oncol 2005, 23:1819-1825.
16. Chau I, Norman AR, Cunningham D, et al.: A randomized comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Ann Oncol 2005, 16:549-557.
17. Hickish T, Boni C, Navarro M, et al.: FOLFOX4 as adjuvant treatment for stage II colon cancer: subpopulation data from the MOSAIC trial [abstract]. Proc ASCO 2004, 22:274a.
18. Andre T, Boni C, Mounedji-Boudiaf L, et al.: Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004, 350:2343-2351.
19. Andre T, Tournigand C, Achille E, et al.: Adjuvant treatment of colon cancer MOSAIC study's main results. Bull Cancer 2006, 93(Suppl 1):S5-S9.
20. Wolmark N, Colangelo L, Wieand S: National Surgical Adjuvant Breast and Bowel Project trials in colon cancer. Semin Oncol 2001, 28(Suppl 1):9-13.
21. Kuebler JP, Wieand HS, O'Connell MJ, et al.: Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 2007, 25:2198-2204.
22. Twelves CJ: Xeloda in Adjuvant Colon Cancer Therapy (X-ACT) trial: Overview of efficacy, safety, and cost-effectiveness. Clin Colorectal Cancer 2006, 6:278-287.
23. Cassidy J, Douillard JY, Twelves CJ, et al.: Pharmacocconomic analysis of adjuvant oral capecitabine vs. intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial. Br J Cancer 2006, 94:1122-1129.
24. Lembersky BC, Wieand HS, Petrelli NJ, et al.: Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol 2006, 24:2059-2064.
25. Yothers G, Kopec JA, Ganz PA, et al.: A comparison of quality of life in colon cancer patients receiving adjuvant uracil/ftorafur + lcucovorin versus 5-fluorottracil + leucovorin in NSABP C-06. Proc ASCO 2005, 23:8080a.
26. Smith R, Wickerham DL, Wieand HS, et al.: UFT plus calcium folinate vs. 5-FU plus calcium folinate in colon cancer. Oncology (Williston Park) 1999, 13(Suppl 3):44-47.
27. Punt CJ, Nagy A, Douillard JY, et al.: Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomized study. Lancet 2002, 360:671-677.
28. Fields ALA, Keller AM, Schwartzberg L, et al.: Edrecolomab (17-1A antibody) (EDR) in combination with 5-fluorouracil (FU) based chemotherapy in the adjuvant treatment of stage III colon cancer: results of a randomized North American phase III study (abstract]. Proc ASCO 2002, 21:128a.
29. Armstrong A, Eck SL: EpCAM: a new therapeutic target for an old cancer antigen. Cancer Biol Ther 2003, 2:320-326.
30. Hartung G, Hofheinz RD, Dencausse Y, et al.: Adjuvant therapy with edrecolomab versus observation in stage II colon cancer: a multicenter randomized phase III study. Onkologie 2005, 28:347-350.
31. Colacchio T, Niedzwiecki D, Compton C, et al.: Phase III trial of adjuvant immunotherapy with MOAb 17-1A following resection for stage II adenocarcinoma of the colon (CALGB 9581) [abstract]. Proc ASCO 2004, 23:3522.
32. Wolmark N, Bryant J, Smith R, et al.: Adjuvant 5-fluorouracil and leucovorin with or without interferon alfa-2a in colon carcinoma: National Surgical Adjuvant Breast and Bowel Project protocol C-05. J Natl Cancer Inst 1998, 90:1810-1816.
33. Saltz LB, Niedzwiecki D, Hollis D, et al.: Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in stage III colon cancer (intergroup trial CALGB C89803) [abstract]. J Clin Oncol Proc ASCO 2004, 22:3500a.
34. Van Cutsem E, Labianca R, Hossfeld D, et al.: Randomized phase III trial comparing infused irinotecan/5-fluorouracil (5-FU)/folinic acid (IF) versus 5-FU/FA (F) in stage III colon cancer patients (pts). PETACC 3 [abstract]. Proc ASCO 2005, 23:8a.
35. Ychou M, Raoul J, Douillard J, et al.: A phase III randomized trial of LVSFU2+CPT-11 vs. LV5FU2 alone in adjuvant high risk colon cancer (FNCLCC Accord02/FFCD9802) [abstract]. Proc ASCO 2005, 23:3502a.
36. Moertel CG, Fleming TR, Macdonald JS, et al.: Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. J Clin Oncol 1995, 13:2936-2943.
37. Mamounas E, Wieand S, WS, Wolmark N, et al.: Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol 1999, 17:1349-1355.
38. Gray RG, Barnwell J, Hills R, et al.: QUASAR: a randomized study of adjuvant chemotherapy vs. observation including 3238 colorectal cancer patients. J Clin Oncol 2004, 22(Suppl):245a.
39. Benson Al, Schrag D, Somerfield MR, et al.: American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004, 22:3408-3419.
40. Cancer Care Ontario: Practice guidelines. http://www.cancercare.on.ca. Accessed April 20, 2007.
41. National Comprehensive Cancer Network: Practice guidelines in oncology. http://www.nccn.org/professionals/physician_gls/PDF/ colon.pdf. Accessed May 2007.
42. Buyse M, Piedbois P: Should Dukes' B patients receive adjuvant therapy? A statistical perspective. Semin Oncol 2001, 28(Suppl 1):20-24.
43. Watanabe T, Wu TT, Catalano PJ, et al.: Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 2001, 344:1196-1206.
44. Allegra CJ, Paik S, Colangelo LH, et al.: Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. J Clin Oncol 2003, 21:241-250.
45. Kim GP, Colangelo LH, Wieand HS, et al.: Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. J Clin Oncol 2007, 25:767-772.
46. Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science 1993, 260:816-819.
47. Johnston PG, Mulligan K, Kay E, et al.: A genetic signature of relapse in stage 11 colorectal cancer derived from formalin fixed paraffin embedded tissue (FFPE) tissue using a unique disease specific colorectal array [abstract]. J Clin Oncol Proc ASCO 2006, 24:3519.